Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Ammerman

Neurological Surgery Washington, DC Medical Doctor

NPI 1043361124 CMS profile 138496

3301 New Mexico Ave Nw, Suite 352, Washington, DC 20016

Open in the dashboard

General payments

$103,537

135 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Ammerman of Washington, DC is reported in the CMS Open Payments database as having received $103,537 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,781 4
2024 General $1,560 3
2023 General $23,095 14
2022 General $11,147 21
2021 General $11,265 23
2020 General $14,604 24
2019 General $38,084 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Ammerman
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Joshua Ammerman were reported at $3,781. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Joshua Ammerman Neurological Surgery median Middle half National median
2019 $38,084 $582 $138–$3,006 $163
2020 $14,604 $294 $76–$2,174 $114
2021 $11,265 $387 $105–$2,432 $132
2022 $11,147 $542 $139–$2,989 $149
2023 $23,095 $534 $145–$2,697 $160
2024 $1,560 $574 $155–$3,046 $164
2025 $3,781 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Centinel Spine, LLC $23,355 10 payments
  2. Globus Medical, Inc. $18,486 26 payments
  3. Medtronic USA, Inc. $15,666 8 payments
  4. Medtronic, Inc. $11,351 10 payments
  5. icotec Medical Inc. $10,500 2 payments
  6. The Institute of Musculoskeletal Science and Education $9,986 19 payments
  7. Integrity Implants Inc $7,012 18 payments
  8. Camber Spine Technologies $2,533 10 payments
  9. Locate Bio Inc $1,125 1 payment
  10. NuVasive, Inc. $985 3 payments
  11. Other $2,537 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $83,388 48 payments
  2. Travel and Lodging $6,589 29 payments
  3. Royalty or License $5,556 13 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,500 2 payments
  5. Food and Beverage $1,554 40 payments
  6. Gift $575 2 payments
  7. Honoraria $375 1 payment
Products named General payments · program years 2019–2025
  1. PRODISC C SK $20,315 6 payments
  2. Precision TLIF $14,226 12 payments
  3. Vader one Pedicle System MIS $10,500 2 payments
  4. CD HORIZON $10,091 5 payments
  5. CAPSTONE $5,075 2 payments
  6. Linesider $3,968 16 payments
  7. Spira $3,130 7 payments
  8. PRODISC L $3,022 2 payments
  9. FlareHawk $3,000 1 payment
  10. Simplify Cervical Artificial Disc $2,375 2 payments
  11. Other $15,805 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

201

Median for Neurosurgery: 83

Drug cost

$4,227

Median for Neurosurgery: $872

Branded share of claims

17.4%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pentazocine-Naloxone Hcl Pentazocine Hcl/Naloxone Hcl Brand 12 $2,518
Gabapentin Generic 80 $945
Methylprednisolone Generic 28 $278
Pregabalin Generic 11 $154
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $143
Diclofenac Sodium Generic 13 $97
Methocarbamol Generic 19 $72
Meloxicam Generic 15 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$88,307

Medicare's payments for the services billed

Medicare patients

313

Average age 77

Services billed

531

175 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Osteoporosis 26%
Ischemic heart disease 24%
Cancer 22%
Depression 20%
Diabetes 16%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record